If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIxico Regulatory News (IXI)

Share Price Information for Ixico (IXI)

Share Price is delayed by 15 minutes
Get Live Data
8.25    0.00 (0.00%)
Bid:
8.00
Ask:
8.50
Spread: 0.50 (6.25%)
Market Cap: £18.07m
IXI Live PriceLast checked at - London Stock Exchange

Intraday Ixico Share Chart

Annual Information Update

6 Feb 2012 09:25

RNS Number : 8480W
Phytopharm PLC
06 February 2012
 

Phytopharm plc

 

Annual Information Update

Phytopharm plc (the Company) announces that, in accordance with the requirements of Prospectus Rule 5.2 issued by the Financial Services Authority, and following publication of the Annual Report on 6 February 2012, the following information has been published or made available to the public between 8 February 2011 and 6 February 2012 inclusive, in compliance with laws and rules dealing with the regulation of securities, issuers of securities and securities markets.

1. Announcements made via the Regulatory Information Service ("RIS")

All the announcements listed below were published through a regulatory information service on the dates indicated. Copies can be obtained from the London Stock Exchange website, http://www.londonstockexchange.com or from the Company's website www.phytopharm.com

Date of publication

Title

2 February 2012

Appointment of Non-Executive Director

27 January 2012

Publication of 2011 annual report

16 January 2012

Research update

11 January 2012

Block listing cancellation

3 January 2012

Block listing interim review

28 November 2011

Director/PDMR shareholding

28 November 2011

Director/PDMR shareholding

24 November 2011

Final results

8 November 2011

Notice of results

7 November 2011

Block listing interim review

4 October 2011

Research update

29 September 2011

Research update

16 August 2011

Interim management statement

28 July 2011

Research update

12 July 2011

Block listing interim review

5 July 2011

Total voting rights

17 June 2011

Block listing interim review

26 May 2011

Half yearly report

17 May 2011

Notice of results

5 May 2011

Block listing interim review

31 March 2011

Results of AGM

2 March 2011

Holding(s) in Company

15 February 2011

Interim management statement

7 February 2011

Annual information update

2. Documents published or sent to Shareholders or submitted to the FSA including those filed with the National Storage Mechanism:

Date of publication

Title

27 January 2012

Annual Report 2011

26 May 2011

Interim Report 2011

30 March 2011

AGM resolutions 2011

The 2011 Interim and 2011 Annual reports are available on the Company's website www.phytopharm.com

3. Documents filed at Companies House

The following documents were files at Companies House. Copies of these documents can be obtained from the Companies House website at www.companieshouse.gov.uk, or Companies House, Crown Way, Cardiff CF14 3UZ

Date of Publication

Title

2 January 2012

Form AP01 Appointment of Director

27 January 2012

Annual Report 2011

15 December 2011

Form AR01 Annual return

5 December 2011

Form AD02 Single alternative inspection location

6 June 2011

Form AH01 Return of allotment of shares on 6 June 2011

31 March 2011

AGM resolutions

Copies of all documents referred to above are also available for inspection at the Company's registered office (Lakeview House, 2 Lakeview Court, Ermine Business Park, Huntingdon, Cambridgeshire PE29 6UA, United Kingdom) during normal business hours or by written request from the Company Secretary.

This annual information is required by, and is being made pursuant to, Article 10 of the Prospectus Directive as implemented by the UK Prospectus Rule 5.2 and not for any other purpose and neither the Company, nor any other person, takes any responsibility for, or makes any representation, express of implied, as to the accuracy or completeness of, the information which it contains. The information is not necessarily up to date as at the date of this annual information update and the Company does not undertake any obligation to update any such information in the future. Neither this annual information update, not referred to in it, constitutes, by virtue of this communication, an offer of securities addressed to any person and it should not be relied on by any person.

For further information, please contact:

Zoe McGowan, Company Secretary

Phytopharm plc Tel No: +44 (0)1480 437697

Further information about Phytopharm can be found on the Company's website www.phytopharm.com

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
AIUEANAKEAAAEEF
Date   Source Headline
7th Feb 20237:00 amRNSTrading Update
31st Jan 20234:35 pmRNSPrice Monitoring Extension
31st Jan 20232:05 pmRNSSecond Price Monitoring Extn
31st Jan 20232:00 pmRNSPrice Monitoring Extension
31st Jan 202311:05 amRNSSecond Price Monitoring Extn
31st Jan 202311:00 amRNSPrice Monitoring Extension
27th Jan 20231:00 pmRNSResult of AGM
3rd Jan 20237:00 amRNSTotal Voting Rights
22nd Dec 202212:18 pmRNSDirector Bed & ISA Dealing
13th Dec 20227:00 amRNSPDMR Exercise of Options
9th Dec 20229:05 amRNSContract Win
8th Dec 20223:34 pmRNSContract Update
7th Dec 20227:00 amRNSFinancial Results for the year ended 30 Sept 2022
21st Nov 20227:00 amRNSNotice of Results and Investor Presentation
25th Oct 20227:00 amRNSTrading Update
21st Sep 202210:35 amRNSHD-IH Consortium
14th Sep 20227:00 amRNSGrant of Share Options
1st Sep 20227:00 amRNSTrading Update and FY2023 Guidance
4th Aug 20227:00 amRNSContract Win
26th Jul 202211:22 amRNSContract Win - Replacement
21st Jul 20227:00 amRNSContract Win
14th Jun 20227:00 amRNSContract Extension
24th May 20227:00 amRNSHalf-year Report and Trading Update
16th May 20227:00 amRNSInvestor Presentation
10th May 20227:00 amRNSConsortium Agreement in Huntington's Disease
25th Apr 20227:00 amRNSTrading Update
21st Apr 20227:00 amRNSNew Contract Win
8th Mar 20227:00 amRNSContract worth circa £800k
14th Feb 20227:00 amRNSLaunch of IXIQ.Ai Deep learning AI-based platform
8th Feb 202212:30 pmRNSHolding(s) in Company
8th Feb 20227:00 amRNSContract award worth circa £1.0m
31st Jan 20227:00 amRNSAppointment of Senior Therapeutic Advisor
26th Jan 20227:00 amRNSDementia collaboration
21st Jan 20227:00 amRNSNon-Executive Director Appointment
20th Jan 202210:50 amRNSResult of AGM
20th Jan 20227:00 amRNSHuntington’s disease contract update
10th Jan 20227:00 amRNSGrant of share options
7th Dec 20217:00 amRNSFinancial Results for the year ended 30 Sept 2021
22nd Nov 20217:00 amRNSNotice of Results
1st Nov 20216:08 pmRNSHolding(s) in Company
1st Nov 20217:00 amRNSNew contract worth >£1.0m
20th Oct 20214:27 pmRNSContract update
18th Oct 20217:00 amRNSTrading Update for year ended 30 September 2021
22nd Sep 20217:00 amRNSNew contract worth >$750k
20th Sep 20217:00 amRNSPhase II HD contract with new client worth >$500K
8th Sep 20217:00 amRNSPhase I MSA contract award worth >$500k
6th Aug 20217:00 amRNSTrading Update
23rd Jun 20213:32 pmRNSIssue of Equity
21st Jun 20212:31 pmRNSHolding(s) in Company
15th Jun 20217:00 amRNSFurther investment in Ixico plc

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.